Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative
Dominant-activating mutations in the RET (rear-ranged during transfection) proto-oncogene, which encodes a receptor tyrosine kinase, is often associated with the development of medullary thyroid carcinoma (MTC). The proximal promoter region of the RET gene consists of a guanine-rich sequence contain...
Main Authors: | , |
---|---|
Other Authors: | |
Language: | en |
Published: |
SPANDIDOS PUBL LTD
2017
|
Subjects: | |
Online Access: | http://hdl.handle.net/10150/624673 http://arizona.openrepository.com/arizona/handle/10150/624673 |
id |
ndltd-arizona.edu-oai-arizona.openrepository.com-10150-624673 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-arizona.edu-oai-arizona.openrepository.com-10150-6246732017-07-14T03:00:35Z Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative Kumarasamy, Vishnu Sun, Daekyu Univ Arizona, Coll Pharm Univ Arizona, Arizona Canc Ctr College of Pharmacy, University of Arizona, Tucson, AZ 85719, USA College of Pharmacy, University of Arizona, Tucson, AZ 85719, USA RET medullary thyroid carcinoma ellipticine G-quadruplex Dominant-activating mutations in the RET (rear-ranged during transfection) proto-oncogene, which encodes a receptor tyrosine kinase, is often associated with the development of medullary thyroid carcinoma (MTC). The proximal promoter region of the RET gene consists of a guanine-rich sequence containing five runs of three consecutive guanine residues that serve as the binding site for transcriptional factors. As we have recently shown, this stretch of nucleotides in the promoter region is highly dynamic in nature and tend to form non-B DNA secondary structures called G-quadruplexes, which suppress the transcription of the RET gene. In the present study, ellipticine and its derivatives were identified as excellent RET G-quadruplex stabilizing agents. Circular dichroism (CD) spectroscopic studies revealed that the incorporation of a piperidine ring in an ellipticine derivative, NSC311153 improves its binding with the G-quadruplex structure and the stability induced by this compound is more potent than ellipticine. Furthermore, this compound also interfered with the transcriptional mechanism of the RET gene in an MTC derived cell line, TT cells and significantly decreased the endogenous RET protein expression. We demonstrated the specificity of NSC311153 by using papillary thyroid carcinoma (PTC) cells, the TPC1 cell line which lacks the G-quadruplex forming sequence in the promoter region due to chromosomal rearrangement. The RET downregulation selectively suppresses cell proliferation by inhibiting the intracellular Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways in the TT cells. In the present study, we also showed that the systemic administration of a water soluble NSC311153 analog in a mouse MTC xenograft model inhibited the tumor growth through RET downregulation. 2017-05-11 Article Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative 2017 International Journal of Oncology 1019-6439 1791-2423 10.3892/ijo.2017.3994 http://hdl.handle.net/10150/624673 http://arizona.openrepository.com/arizona/handle/10150/624673 International Journal of Oncology en http://www.spandidos-publications.com/10.3892/ijo.2017.3994 © SPANDIDOS PUBLICATIONS UK LTD. SPANDIDOS PUBL LTD |
collection |
NDLTD |
language |
en |
sources |
NDLTD |
topic |
RET medullary thyroid carcinoma ellipticine G-quadruplex |
spellingShingle |
RET medullary thyroid carcinoma ellipticine G-quadruplex Kumarasamy, Vishnu Sun, Daekyu Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative |
description |
Dominant-activating mutations in the RET (rear-ranged during transfection) proto-oncogene, which encodes a receptor tyrosine kinase, is often associated with the development of medullary thyroid carcinoma (MTC). The proximal promoter region of the RET gene consists of a guanine-rich sequence containing five runs of three consecutive guanine residues that serve as the binding site for transcriptional factors. As we have recently shown, this stretch of nucleotides in the promoter region is highly dynamic in nature and tend to form non-B DNA secondary structures called G-quadruplexes, which suppress the transcription of the RET gene. In the present study, ellipticine and its derivatives were identified as excellent RET G-quadruplex stabilizing agents. Circular dichroism (CD) spectroscopic studies revealed that the incorporation of a piperidine ring in an ellipticine derivative, NSC311153 improves its binding with the G-quadruplex structure and the stability induced by this compound is more potent than ellipticine. Furthermore, this compound also interfered with the transcriptional mechanism of the RET gene in an MTC derived cell line, TT cells and significantly decreased the endogenous RET protein expression. We demonstrated the specificity of NSC311153 by using papillary thyroid carcinoma (PTC) cells, the TPC1 cell line which lacks the G-quadruplex forming sequence in the promoter region due to chromosomal rearrangement. The RET downregulation selectively suppresses cell proliferation by inhibiting the intracellular Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways in the TT cells. In the present study, we also showed that the systemic administration of a water soluble NSC311153 analog in a mouse MTC xenograft model inhibited the tumor growth through RET downregulation. |
author2 |
Univ Arizona, Coll Pharm |
author_facet |
Univ Arizona, Coll Pharm Kumarasamy, Vishnu Sun, Daekyu |
author |
Kumarasamy, Vishnu Sun, Daekyu |
author_sort |
Kumarasamy, Vishnu |
title |
Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative |
title_short |
Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative |
title_full |
Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative |
title_fullStr |
Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative |
title_full_unstemmed |
Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative |
title_sort |
demonstration of a potent ret transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative |
publisher |
SPANDIDOS PUBL LTD |
publishDate |
2017 |
url |
http://hdl.handle.net/10150/624673 http://arizona.openrepository.com/arizona/handle/10150/624673 |
work_keys_str_mv |
AT kumarasamyvishnu demonstrationofapotentrettranscriptionalinhibitorforthetreatmentofmedullarythyroidcarcinomabasedonanellipticinederivative AT sundaekyu demonstrationofapotentrettranscriptionalinhibitorforthetreatmentofmedullarythyroidcarcinomabasedonanellipticinederivative |
_version_ |
1718496526174519296 |